OXB is a specialist advanced-therapy lentivirus-based vector biopharma company. It offers vector manufacturing and development services and is developing its own proprietary drug candidates. In addition to LentiVector® service contracts, OXB will receive royalties on commercial therapies developed with its platform. This deal structure was established with Novartis for KymriahPPPTM in 2017PP and was followed post-period end by a collaboration and licence agreement (adopting a similar structure) with Bioverativ Inc (BIVV). Investment in manufacturing is being made to increase capacity and meet demand from further such deals.
If you'd like to be introduced to the team at Oxford BioMedica, get in touch.Request a meeting